Context:

• The Union Ministry of Health and Family Welfare has initiated a process to mandate CCTV surveillance for the sale of prescription drugs across India by early 2027.
• While the proposal aims to curb the illegal sale and misuse of medicines, it raises concerns regarding the Right to Privacy, proportionality and regulatory accountability.

Potential Benefits of CCTV Surveillance:

• CCTV surveillance could strengthen the enforcement of prescription requirements and improve transparency in pharmaceutical sales through -
  • Evidence-based enforcement: Video footage can establish whether a prescription was presented, which medicine was dispensed and when the transaction occurred.
  • Accountability: It can help drug inspectors investigate complaints against pharmacies repeatedly violating prescription requirements.
  • Prevention of drug diversion: Surveillance could strengthen the monitoring of Schedule H1 and Schedule X medicines, which are subject to stricter regulatory controls due to their potential for misuse.
  • Deterrence: The possibility of being monitored may discourage pharmacies from dispensing prescription medicines without valid prescriptions.
• However, the effectiveness of this approach depends on whether surveillance addresses the actual causes of regulatory violations.

Privacy Concerns and Risks of Mass Surveillance:

• Exposure of sensitive health information:
  • Reveal intimate details: A pharmacy is not merely a retail outlet; it is a place where individuals access sensitive healthcare services like purchases of antidepressants, anti-epileptic drugs, HIV medicines, fertility treatments, abortion pills, psychiatric medicines and cancer drugs.
  • Risk of profiling: Combining a person's identity, pharmacy visits, medicines purchased and transaction timings could create a detailed record of their health-related behaviour.
  • Potential misuse: Unauthorised access, copying, sharing or integration of footage with facial-recognition systems could expose individuals to discrimination, stigma and violations of privacy.
  • Chilling effect: Fear of surveillance may discourage individuals from seeking essential medicines, particularly for sensitive health conditions.
• Questions of data governance:
  • The proposed system raises several concerns -
    • Who will have access to the footage—drug inspectors, police or other government agencies?
    • Can the recordings be used for purposes unrelated to pharmaceutical regulation?
    • How long will the footage be retained, and what safeguards will prevent unauthorised access?
    • Will citizens be informed when their footage is accessed?
  • Without clear safeguards, CCTV surveillance could become a tool for excessive state monitoring.

Limitations of CCTV as a Regulatory Tool:

• Checking genuinity: CCTV can document a transaction but cannot independently establish whether a prescription is genuine or medically appropriate.
• Limited verification: A camera can record the presentation of a prescription but cannot verify its authenticity or clinical validity.
• Implementation challenges: Installing and maintaining surveillance systems across pharmacies could impose financial and administrative burdens.
• Regulatory gaps: Greater data collection does not necessarily translate into better enforcement if inspections are inadequate or violations go unpunished. 

Constitutional and Legal Dimensions:

• The Supreme Court's judgment in Justice K. S. Puttaswamy v. Union of India (2017) recognised privacy as a fundamental right under Article 21 of the Constitution.
• Any restriction on privacy must satisfy the principles of -
  • Legality: Surveillance must have a clear legal basis.
  • Necessity: It must serve a legitimate state objective and be necessary to achieve it.
  • Proportionality: The intrusion into individual privacy must be proportionate to the intended objective.
  • Procedural safeguards: Adequate protections must prevent arbitrary surveillance and misuse of personal information.
• The government must demonstrate that blanket CCTV surveillance is necessary and that less intrusive alternatives would not achieve the same regulatory objectives. 

Way Forward - A Targeted and Proportionate Approach:

• Risk-based surveillance: Prioritise stricter monitoring of high-risk medicines and pharmacies with a history of violations rather than imposing blanket surveillance.
• Strengthen existing enforcement:
  • India already has prescription requirements, pharmacy licensing conditions, inspection mechanisms and specific regulations governing Schedule H, H1 and X medicines.
  • Strengthening their implementation may address illegal sales without subjecting every prescription transaction to surveillance.
  • Improve the capacity of drug inspectors, conduct regular inspections and ensure timely action against violations.
• Data protection safeguards: Establish clear rules on access, retention, deletion and permissible use of CCTV footage.
• Independent oversight: Introduce accountability mechanisms to monitor access to recordings and prevent their misuse.
• Technology with safeguards: Explore digital prescription verification and electronic audit trails as less intrusive alternatives.

Conclusion:

• The proposed CCTV mandate highlights the tension between public health regulation and the fundamental right to privacy.
• While technology can improve pharmaceutical oversight, indiscriminate surveillance may create new risks without adequately addressing existing enforcement failures.
• A targeted, transparent and proportionate regulatory framework is essential to ensure that public health objectives are achieved without compromising individual dignity and privacy.